Ribomic specializes in the development of aptamer therapeutics, which are nucleic acid molecules that can bind to specific proteins, thereby inhibiting or controlling their activity. This technology leverages the unique structural properties of RNA, allowing for the creation of three-dimensional shapes that fit the target proteins more effectively than traditional antibodies. Aptamers offer several advantages, including higher binding affinity, fewer limitations regarding target proteins, easier chemical modifications, and lower antigenicity. Ribomic employs a proprietary drug discovery platform known as the Ribomic Aptamer Refined Therapeutics (RiboART) system, which utilizes the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technique to isolate and amplify RNA sequences that bind tightly to target proteins.

The company’s pipeline includes promising candidates for various diseases, such as RBM-007 for wet age-related macular degeneration and achondroplasia, and RBM-011 for pulmonary arterial hypertension. These candidates demonstrate the potential of aptamer therapeutics to address unmet medical needs by targeting specific pathways involved in disease progression. Ribomic's approach combines in-house drug discovery with collaborations with pharmaceutical companies, allowing for the development of first-in-class therapeutic aptamers that can be licensed out for further clinical studies and commercialization.

Japan

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. It develops drugs in the areas of pain, heart failure, and other diseases. The company has 25 employees as of March 2023 and is headquartered in Minato, Tokyo.

Ribomic

Company Details